{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:34:52Z","timestamp":1783470892555,"version":"3.55.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.nefro.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T05:47:10Z","timestamp":1506145630000},"page":"478-491","source":"Crossref","is-referenced-by-count":13,"title":["Microangiopat\u00eda tromb\u00f3tica secundaria y eculizumab: una opci\u00f3n terap\u00e9utica razonable"],"prefix":"10.1016","volume":"37","author":[{"given":"Elena","family":"Rom\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mendiz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Praga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2017.01.006_bib0755","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement-mediated thrombotic microangiopathies: Pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.nefro.2017.01.006_bib0760","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOT.0b013e32836370ce","article-title":"Physiological and therapeutic complement regulators in kidney transplantation","volume":"18","author":"Roumenina","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib0765","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","article-title":"An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document","volume":"35","author":"Campistol","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2017.01.006_bib0770","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0775","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ndt\/gfn586","article-title":"Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis","volume":"24","author":"Chen","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib0780","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2215\/CJN.07910814","article-title":"Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis","volume":"10","author":"Chen","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0785","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib0790","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and efficacy of CCX168 in subjects with ANCA-associated vasculitis, 2014. [consultado 16 abril 2016]. Disponible en: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01363388"},{"key":"10.1016\/j.nefro.2017.01.006_bib0795","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000368591","article-title":"Complement and glomerular diseases","volume":"128","author":"Popat","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefro.2017.01.006_bib0800","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0805","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1681\/ASN.2010060647","article-title":"Complement factor H deficiency accelerates development of lupus nephritis","volume":"22","author":"Bao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0810","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10157-010-0300-5","article-title":"Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy","volume":"14","author":"Gharbi","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0815","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nefro.2017.01.006_bib0820","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/art.30222","article-title":"The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL\/lpr mice","volume":"63","author":"Sekine","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefro.2017.01.006_bib0825","unstructured":"Furie R, Matis L, Rollins S. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus. En: Innovative Therapies in Autoimmune Diseases, Resumen presentado en: American College of Rheumatology 68th Annual Scientific Meeting; San Antonio, TX, 19 Oct 2004."},{"key":"10.1016\/j.nefro.2017.01.006_bib0830","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","article-title":"Targeting the complement system in systemic lupus erythematosus and other diseases","volume":"148","author":"Barilla-Labarca","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0835","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: Efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2017.01.006_bib0840","first-page":"2286","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefro.2017.01.006_bib0845","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefro.2017.01.006_bib0850","first-page":"704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: A case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0855","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefro.2017.01.006_bib0860","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0865","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nefro.2017.01.006_bib0870","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib0875","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib0880","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves postransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib0885","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TP.0000000000000267","article-title":"A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab","volume":"98","author":"Bakhtar","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib0890","article-title":"From malignant hypertension to hypertension-MOD: A modern definition for an old but still dangerous emergency","author":"Cremer","year":"2015","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.nefro.2017.01.006_bib0895","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1291\/hypres.28.89","article-title":"Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)\/thrombotic thrombocytopenic purpura (TTP): Can we differentiate one from the other?","volume":"28","author":"Shibagaki","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1016\/j.nefro.2017.01.006_bib0900","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1093\/ndt\/gfq143","article-title":"Long-term renal survival in malignant hypertension","volume":"25","author":"Gonzalez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib0905","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.nefro.2017.01.006_bib0910","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/HYPERTENSIONAHA.107.103127","article-title":"Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension","volume":"51","author":"Van den Born","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.nefro.2017.01.006_bib0915","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"Van den Born","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.nefro.2017.01.006_bib0920","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5414\/CNP73147","article-title":"Severe renal failure and microangiopathic hemolysis induced by malignant hypertension--case series and review of literature","volume":"73","author":"Shavit","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0925","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040620715571076","article-title":"Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura","volume":"6","author":"Khanal","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0930","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: Consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib0935","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ki.2013.340","article-title":"Toward a working definition of C3 glomerulopathy by immunofluorescence","volume":"85","author":"Hou","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib0940","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: Core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2017.01.006_bib0945","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/01.ASN.0000115702.28859.A7","article-title":"Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: Report and genetic analysis of 16 cases","volume":"15","author":"Dragon-Durey","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0950","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: One target, two diseases","volume":"194","author":"Blanc","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0960","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib1505","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ckj\/sfs190","article-title":"Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome","volume":"6","author":"Janssen van Doorn","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2017.01.006_bib0965","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/ndt\/gfr436","article-title":"Three kidneys, two diseases, one antibody","volume":"26","author":"Lorcy","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib0970","first-page":"793","article-title":"Atypical hemolytic uremic syndrome with membranoproliferative glomerulonephritis","volume":"50","author":"Mehta","year":"2013","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.nefro.2017.01.006_bib0975","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib0980","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/MNH.0b013e32835da24c","article-title":"Treatment options for C3 glomerulopathy","volume":"22","author":"Nester","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefro.2017.01.006_bib0985","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2215\/CJN.01360215","article-title":"Eculizumab in pediatric dense deposit disease","volume":"10","author":"Oosterveld","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib0990","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","author":"Le Quintrec","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2017.01.006_bib0995","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ckj\/sfv065","article-title":"Timing of eculizumab therapy for C3 glomerulonephritis","volume":"8","author":"Rodriguez-Osorio","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2017.01.006_bib1000","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","article-title":"A case of C3 glomerulonephritis successfully treated with eculizumab","volume":"30","author":"Payette","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000368592","article-title":"Eculizumab in the treatment of membranoproliferative glomerulonephritis","volume":"128","author":"Bomback","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefro.2017.01.006_bib1010","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current Understanding of the Role of Complement in IgA Nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1015","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ckj\/sfv095","article-title":"Rapidly progressive IgA nephropathy: A form of vasculitis or a complement-mediated disease","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2017.01.006_bib1025","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5414\/CN108000","article-title":"Hemolytic uremic syndrome complicated with IgA nephropathy: A case report and literature review","volume":"83","author":"Wang","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1040","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.molimm.2008.12.002","article-title":"Is complement factor H a susceptibility factor for IgA nephropathy","volume":"46","author":"Edey","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00431-010-1279-3","article-title":"IgA nephropathy associated with a novel N-terminal mutation in factor H","volume":"170","author":"Schmitt","year":"2011","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.nefro.2017.01.006_bib1050","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00467-014-2863-y","article-title":"Eculizumab treatment for rescue of renal function in IgA nephropathy","volume":"29","author":"Rosenblad","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: Proof of principle and conundrum","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2017.01.006_bib1060","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/ndt\/gft220","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","author":"Manenti","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1065","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMc1106619","article-title":"Eculizumab and refractory membranoproliferative glomerulonephritis","volume":"366","author":"Radhakrishnan","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nefro.2017.01.006_bib1070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1075","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.2215\/CJN.13121211","article-title":"Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy","volume":"7","author":"Fakhouri","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-159-1-201307020-00023","article-title":"Successful treatment of the pospartum atypical hemolytic uremic syndrome with eculizumab","volume":"159","author":"Zschiedrich","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefro.2017.01.006_bib1085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ckj\/sfs185","article-title":"Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: Terminal complement activity assessment in clinical practice","volume":"6","author":"Delmas","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2017.01.006_bib1090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","article-title":"Eculizumab for atypical hemolytic uremic syndrome in pregnancy","volume":"122","author":"Ardissino","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1095","first-page":"1421","article-title":"Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome","volume":"93","author":"Ca\u00f1igral","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1752-1947-8-307","article-title":"Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: A case report","volume":"8","author":"Kourouklaris","year":"2014","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.nefro.2017.01.006_bib1105","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40620-015-0173-5","article-title":"Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: Insights for optimizing management","volume":"28","author":"De Sousa Amorim","year":"2015","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1110","doi-asserted-by":"crossref","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort","volume":"8","author":"Salmon","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.nefro.2017.01.006_bib1115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"10.1016\/j.nefro.2017.01.006_bib1120","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1125","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","author":"Dhakal","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.nefro.2017.01.006_bib1130","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1135","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1046\/j.1600-6143.2003.00222.x","article-title":"Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation","volume":"3","author":"Karthikeyan","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2017.01.006_bib1145","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","article-title":"De novo thrombotic microangiopathy after kidney transplantation: Clinical features, treatment, and long-term patient and graft survival","volume":"44","author":"Caires","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nefro.2017.01.006_bib1150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nri3225","article-title":"The role of complement in the early immune response to transplantation","volume":"12","author":"Sacks","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1155","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/ajt.12130","article-title":"Complement mediated renal inflammation induced by donor brain death: Role of renal C5a-C5aR interaction","volume":"13","author":"Van Werkhoven","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1160","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2215\/CJN.02200312","article-title":"Clinical analysis of perioperative complement activity during ischemia\/reperfusion injury following renal transplantation","volume":"7","author":"Blogowski","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1165","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/TP.0b013e31827e31c9","article-title":"Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation","volume":"95","author":"De Vries","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1170","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1681\/ASN.2005070698","article-title":"Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia\/reperfusion injury","volume":"17","author":"Thurman","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1175","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1093\/ndt\/gfq717","article-title":"Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation","volume":"26","author":"Damman","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1180","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000321328","article-title":"De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss","volume":"32","author":"De Keyzer","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1185","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1053\/j.ajkd.2004.09.012","article-title":"Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: Successful treatment with intensive plasma exchanges and ganciclovir","volume":"45","author":"Olie","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2017.01.006_bib1190","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/tri.12582","article-title":"Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: Case report and review of the literature","volume":"28","author":"Java","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib1195","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/00007890-199806270-00018","article-title":"Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: A new treatment strategy","volume":"65","author":"Jeejeebhoy","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1200","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2017.01.006_bib1205","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles","volume":"24","author":"Renner","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1210","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: Hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2017.01.006_bib1215","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.molimm.2009.04.012","article-title":"A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome","volume":"46","author":"Stahl","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1220","first-page":"455","article-title":"Cyclosporin-induced endothelial cell injury","volume":"55","author":"Zoja","year":"1986","journal-title":"Lab Invest"},{"key":"10.1016\/j.nefro.2017.01.006_bib1225","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.transproceed.2012.01.089","article-title":"Apoptosis in endothelial cells by cyclosporine","volume":"44","author":"Hwang","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nefro.2017.01.006_bib1230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.toxlet.2013.01.007","article-title":"Cyclosporine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission","volume":"218","author":"De Arriba","year":"2013","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.nefro.2017.01.006_bib1235","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1240","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: Clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nefro.2017.01.006_bib1245","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nefro.2017.01.006_bib1250","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1600-6143.2005.01047.x","article-title":"Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys","volume":"5","author":"Sartelet","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN108163","article-title":"Eculizumab for drug-induced de novo postransplantation thrombotic microangiopathy: A case report","volume":"83","author":"Safa","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1260","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.transproceed.2011.02.064","article-title":"Eculizumab for the treatment of de novo thrombotic microangiopathy postsimultaneous pancreas-kidney transplantation--a case report","volume":"43","author":"Chandran","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nefro.2017.01.006_bib1265","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.V122.21.1078.1078","article-title":"Successful management of calcineurin induced thrombotic microangiopathy (TMA) with eculizumab after non- renal solid organ transplantation","volume":"122","author":"Broome","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2017.01.006_bib1270","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/TP.0b013e318230c0bd","article-title":"Successful treatment of de novo postransplant thrombotic microangiopathy with eculizumab","volume":"92","author":"Wilson","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1275","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/tri.12551","article-title":"A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab","volume":"28","author":"Morales","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib1280","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1285","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/tri.12396","article-title":"Antibody-mediated rejection despite inhibition of terminal complement","volume":"27","author":"Bentall","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.nefro.2017.01.006_bib1290","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts","volume":"98","author":"Burbach","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1295","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/MOT.0000000000000249","article-title":"Eculizumab use in kidney transplantation","volume":"20","author":"Johnson","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1300","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1305","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1542\/peds.2014-2275","article-title":"Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient","volume":"135","author":"Chehade","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.nefro.2017.01.006_bib1310","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1315","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing autoSCT","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1701830","article-title":"Severe thrombotic microangiopathy: An infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"24","author":"Iacopino","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1325","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1330","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1335","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2009.230","article-title":"Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning","volume":"45","author":"Willems","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1340","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1473-0502(02)00020-4","article-title":"Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver","volume":"27","author":"Daly","year":"2002","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.nefro.2017.01.006_bib1350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2008.419","article-title":"Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy","volume":"44","author":"Inamoto","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1355","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbmt.2012.08.022","article-title":"Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"19","author":"Jodele","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1360","doi-asserted-by":"crossref","first-page":"E39","DOI":"10.1111\/j.1399-3046.2010.01408.x","article-title":"Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation","volume":"16","author":"Jodele","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1365","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbmt.2010.02.006","article-title":"Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation","volume":"16","author":"Glezerman","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1370","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbmt.2009.11.018","article-title":"Hypertension in long-term survivors of pediatric hematopoietic cell transplantation","volume":"16","author":"Hoffmeister","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1375","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2013.07.017","article-title":"Pulmonary hypertension after hematopoietic stem cell transplantation","volume":"19","author":"Dandoy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1380","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.echo.2010.01.003","article-title":"Echocardiographic indexes for the non-invasive evaluation of pulmonary hemodynamics","volume":"23","author":"Milan","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.nefro.2017.01.006_bib1385","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-1101(1998)13:1<16::AID-JCA3>3.0.CO;2-C","article-title":"Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura","volume":"13","author":"Cohen","year":"1998","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nefro.2017.01.006_bib1390","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: A study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2017.01.006_bib1395","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1400","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1537-2995.2012.03776.x","article-title":"Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy","volume":"53","author":"Jodele","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.nefro.2017.01.006_bib1405","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.bmt.1703414","article-title":"Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation","volume":"29","author":"Corti","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1410","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood-2013-07-512707","article-title":"TMA: Beware of complements","volume":"122","author":"Ricklin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2017.01.006_bib1415","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2017.01.006_bib1420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal arteriolar C4d deposition: A novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1425","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2559.1986.tb02593.x","article-title":"Haemolytic-uraemic syndrome in recipients of bone marrow transplants not treated with cyclosporin A","volume":"10","author":"Marshall","year":"1986","journal-title":"Histopathology"},{"key":"10.1016\/j.nefro.2017.01.006_bib1430","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1435","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: A study from the SFGM-TC","volume":"99","author":"De Fontbrune","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2017.01.006_bib1440","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1053\/j.ajkd.2013.02.022","article-title":"Doxorubicin induced thrombotic microangiopathy-2 case reports of this unknown association","volume":"61","author":"Ansari","year":"2013","journal-title":"AJKD"},{"key":"10.1016\/j.nefro.2017.01.006_bib1445","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: Case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1450","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2017.01.006_bib1455","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0034-1375295","article-title":"Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS)","volume":"40","author":"Wurzner","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.nefro.2017.01.006_bib1460","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00467-015-3207-2","article-title":"CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS)","volume":"31","author":"Caillaud","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1465","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1470","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2017.01.006_bib1475","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/sj.bmt.1704513","article-title":"Thrombotic microangiopathy after allogeneic bone marrow transplantation: A pathologic abnormality associated with diverse clinical syndromes","volume":"33","author":"George","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1480","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2215\/CJN.02070508","article-title":"Renal thrombotic microangiopathy after hematopoietic cell transplant: Role of GVHD in pathogenesis","volume":"4","author":"Changsirikulchai","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1485","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.02699.x","article-title":"The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation","volume":"113","author":"Fuge","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nefro.2017.01.006_bib1490","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.V73.7.2018.2018","article-title":"Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation","volume":"73","author":"Holler","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.nefro.2017.01.006_bib1495","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1705454","article-title":"Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease","volume":"38","author":"Wolff","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nefro.2017.01.006_bib1500","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: Results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699517300437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699517300437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T07:52:47Z","timestamp":1659513167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699517300437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":150,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0211699517300437"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2017.01.006","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}